Kamada (KMDA) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a sell rating to a hold rating in a report issued on Friday morning.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Several other equities analysts also recently weighed in on the company. Jefferies Group reiterated a buy rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. ValuEngine upgraded Kamada from a sell rating to a hold rating in a research report on Friday, January 5th. Chardan Capital initiated coverage on Kamada in a research report on Friday, February 2nd. They set a buy rating and a $7.00 target price on the stock. Finally, HC Wainwright reiterated a buy rating on shares of Kamada in a research report on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $7.00.
Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.10. The company had revenue of $35.71 million for the quarter, compared to the consensus estimate of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. equities analysts anticipate that Kamada will post 0.21 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC purchased a new position in Kamada during the fourth quarter valued at $251,000. Jane Street Group LLC purchased a new position in shares of Kamada in the third quarter valued at about $112,000. Analyst IMS Investment Management Services Ltd. lifted its position in shares of Kamada by 125.5% in the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares in the last quarter. Worth Venture Partners LLC purchased a new position in shares of Kamada in the third quarter valued at about $246,000. Finally, Paulson & CO. Inc. lifted its position in shares of Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after acquiring an additional 60,000 shares in the last quarter. Institutional investors own 6.26% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.